Swedish CDMO APL partners with Finnish tech firm CurifyLabs to develop 3D-printed personalized medicines, aiming for market launch by 2025.
Apotek Produktion & Laboratorier (APL), one of Sweden’s largest manufacturers of extemporaneous medicines and a leading CDMO, has joined forces with CurifyLabs, a Finnish health tech company. This partnership aims to enhance medicine administration for children and critically ill patients using innovative 3D printing technology.
3D printing offers several advantages over traditional pharmaceutical processes, including the ability to produce more personalized dosages and dosage forms with flexible shapes and structures. The technology enables precise dosing, which can help reduce side effects in patients.
While APL’s current manufacturing method produces at least 100 capsules per batch, 3D printing technology allows for the creation of precise individual doses. This not only minimizes waste, but also contributes to sustainable pharmaceutical manufacturing. It is all automated where 3D printing will be a much safer place for workers without risk components such as injuries due to constant repetition of bodily motion, or chemicals.
APL Chief Executive Officer Erik Haeffler said in a statement about the new collaboration: “We are very impressed with CurifyLabs’ commitment to supporting us on our journey to address the urgent unmet needs of critically ill patients. 3D printing is an exciting technology that is well-suited to extemporaneous manufacturing. It will give us additional opportunities to fulfill our public policy assignment.”
Charlotta Topelius, the CEO of CurifyLabs, said: “APL has demonstrated its strong capabilities in extemporaneous medicines with high quality and consistency, which will be critical to accelerating our development efforts together. We look forward to combining our strengths to create even greater value for patients needing personalized medicines.”
APL seeks to introduce fully regulated, 3D-printed personalized medicines to Sweden by 2025. The first 3D printers are scheduled for delivery in September 2024.
This collaboration follows CurifyLabs’ recent launch of 3D printable Pharma Inks, making the company one of the first to offer 3D printing of medicine as a scalable and practical service for create customized medicines for patients in pharmacies and hospitals.
Alexa Sipes is a U.S. tech journalist with 5 years of experience, now writing for 360TechInsights. She covers emerging technologies and industry trends across North America, Europe, and Asia. Sipes’ concise reporting offers readers valuable insights into the latest tech news, innovations and the companies behind them.
Feel free to reach out to me at AlexaSipes@360techinsights.com.
